dual glp 1 and gip receptor agonist GIP/GLP-1 agonists: New advances for treating type-2 diabetes GLP-1/GIP Dual Receptor Agonist -

A key feature of the consensus is its endorsement of shared decision-making, taking into account patient goals, preferences, access, and affordability

Glucagon-like peptide-1 (GLP-1) is an incretin hormone released from gut enteroendocrine cells that modulates glucose metabolism by controlling insulin excretion and glucagon secretion and inhibits gastric emptying leading to decreased food intake, thus limiting weight gain

Here is what the evidence says about protecting your bones and muscle on GLP-1 therapy.

Medicare is already spending billions on drugs like Ozempic, and Biden recently proposed expanding access to obesity treatments.

Serious adverse events reported in temporal association with GLP-1 RA exposure included anaphylaxis with bronchospasm (n=4 cases), acute eosinophilic pneumonia (n=1), perioperative aspiration pneumonitis or pneumonia (multiple perioperative cases across two cohort studies and one case series), acute respiratory distress syndrome (ARDS

Indication expansion, such as approvals for additional metabolic and cardiovascular conditions, is broadening patient access and driving adoption